Choosing the right crystal: solid form optimisation for pharmaceutical development

On June 10, Associate Director of Formulation AT BioDuro, Dr Zi Li, presented key aspects of crystalline forms in drug development, share case studies on how solid form optimization can modify drug properties, and discuss preformulation strategies to accelerate preclinical formulation workflows.

This makes solid-state selection a critical decision in early-stage drug development.

When key API properties fall short of development requirements, solid form optimisation - including polymorph screening, salt formation and cocrystallisation - can modify behaviour without altering the underlying chemical structure. Different crystal forms of the same API can also exhibit distinct properties that support separate patent protection, making crystal form an important pillar of IP strategy.

Overall, a comprehensive understanding of solid form landscapes is essential in pharmaceutical development. On June 10, our Associate Director of Formulation, Dr Zi Li, presented key aspects of crystalline forms in drug development, share case studies on how solid form optimization can modify drug properties, and discuss preformulation strategies to accelerate preclinical formulation workflows.

Everything you will learn:

• Understand how polymorphs, salts and cocrystals influence drug performance and formulation viability
• Explore how solid form optimisation can resolve dissolution, stability and processability challenges without changing the underlying molecule
• Learn how crystal form selection supports patent protection and wider intellectual property strategy
• See case studies demonstrating how targeted solid form optimisation has modified API behaviour in practice
• Discover how preformulation studies can accelerate preclinical formulation workflows and de-risk later-stage development